Semanteon Capital Management LP Makes New $745,000 Investment in Evolent Health, Inc. (NYSE:EVH)

Semanteon Capital Management LP acquired a new position in shares of Evolent Health, Inc. (NYSE:EVH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 66,230 shares of the technology company’s stock, valued at approximately $745,000. Semanteon Capital Management LP owned 0.06% of Evolent Health at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Evolent Health in the 4th quarter valued at $31,000. AlphaQuest LLC increased its stake in shares of Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after purchasing an additional 2,358 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Evolent Health in the 4th quarter valued at $61,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Evolent Health by 2,471.9% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock valued at $184,000 after purchasing an additional 6,254 shares during the last quarter.

Insider Transactions at Evolent Health

In other Evolent Health news, President Daniel Joseph Mccarthy acquired 11,040 shares of the stock in a transaction dated Thursday, March 6th. The stock was purchased at an average cost of $9.01 per share, with a total value of $99,470.40. Following the transaction, the president now owns 389,004 shares in the company, valued at approximately $3,504,926.04. The trade was a 2.92 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Diane Holder acquired 2,735 shares of the stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $9.33 per share, with a total value of $25,517.55. Following the completion of the transaction, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. This represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 74,000 shares of company stock valued at $666,315. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Citigroup decreased their price target on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Oppenheimer decreased their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. BTIG Research cut their price objective on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a report on Friday, February 14th. Finally, Stephens cut their price objective on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 21st. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $17.71.

Evolent Health Stock Down 3.5 %

Shares of EVH opened at $9.61 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of -11.72 and a beta of 1.49. Evolent Health, Inc. has a 12 month low of $8.35 and a 12 month high of $33.63. The stock’s 50-day moving average price is $9.93 and its two-hundred day moving average price is $16.26. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH) last announced its earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). The company had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.